Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

SIRT Followed by CIS-GEM Chemotherapy Versus CIS-GEM Chemotherapy Alone as 1st Line Treatment of Patients With Unresectable Intrahepatic Cholangiocarcinoma (SIRCCA)

This study is currently recruiting participants. (see Contacts and Locations)
Verified April 2017 by Sirtex Medical
Information provided by (Responsible Party):
Sirtex Medical Identifier:
First received: May 13, 2016
Last updated: April 4, 2017
Last verified: April 2017
The study will evaluate the benefit of applying Selective Internal Radiation Therapy (SIRT) using SIR-Spheres Y-90 resin microspheres prior to receiving systemic chemotherapy treatment (cisplatin-gemcitabine, or CIS-GEM) in patients with unresectable intrahepatic cholangiocarcinoma. Half of the patients will be randomized to CIS-GEM chemotherapy plus SIRT, and half of the patients will be randomized to CIS-GEM alone.

Condition Intervention
Intrahepatic Cholangiocarcinoma
Drug: Cisplatin-gemcitabine
Device: Radiation: SIRT + chemotherapy (cisplatin-gemcitabine)

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: No masking
Primary Purpose: Treatment
Official Title: Prospective, Multicenter, Randomized, Controlled Study Evaluating SIR-Spheres Y-90 Resin Microspheres Preceding Cisplatin-gemcitabine (CIS-GEM) Chemotherapy Versus CIS-GEM Chemotherapy Alone as First-line Treatment of Patients With Unresectable Intrahepatic Cholangiocarcinoma

Resource links provided by NLM:

Further study details as provided by Sirtex Medical:

Primary Outcome Measures:
  • Survival at 18 months [ Time Frame: 18 months following the date of randomization. ]
    Survival at 18 months is defined as the proportion of patients still alive 18 months from the date of randomization.

Secondary Outcome Measures:
  • Liver-specific progression free survival (PFS) [ Time Frame: From date of randomization to the first documented date of progression in the liver or date of death from any cause, assessed up to 36 months.. ]
  • Progression free survival (PFS) at any site [ Time Frame: From date of randomization to the date of progression at any site until the first date of documented tumor progression at any site or date of death from any cause, assessed up to 36 months. ]
  • Objective response rate by RECIST 1.1 and refined RECIST - liver [ Time Frame: From the date of first treatment until the date of date of first documented progression in the liver, assessed up to 36 months. ]
  • Objective response rate by RECIST 1.1 and refined RECIST - at any site [ Time Frame: From the date of first treatment until progression at any site, assessed up to 36 months. ]
  • Overall Survival [ Time Frame: From date of randomization until the date of death from any cause, assessed up to 36 months. ]
  • Liver surgical resection and ablation rate [ Time Frame: 18 months following the date of randomization. ]
    To assess the number of patients in each arm who are downstaged by protocol therapy and can proceed to liver resection or ablation. The specific assessments will be the classification of resection as R0, R1 or R2, the presence of viable tumor or fibrosis, and the nearest resection margin.

  • Incidence of Adverse Events (Safety and tolerability) [ Time Frame: Informed consent until 28 days post last dose of protocol chemotherapy. ]
    Adverse events as assessed by CTCAE v. 4.0.

Estimated Enrollment: 180
Actual Study Start Date: January 2017
Estimated Study Completion Date: December 2019
Estimated Primary Completion Date: December 2019 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Chemotherapy (Cisplatin-Gemcitabine)
Cisplatin 25mg/m2 in 1000ml 0.9% saline given over 1 hour followed by 500 ml 0.9% saline over 30 minutes, followed by Gemcitabine 1000 mg/m2 in 250-500 ml 0.9% saline over 30 minutes by intravenous infusions on days 1, and 8 of a 21-day cycle.
Drug: Cisplatin-gemcitabine
Systemic chemotherapy
Other Name: CIS-GEM
Experimental: Radiation: SIRT + chemotherapy (Cisplatin-Gemcitabine)
A single treatment of hepatic arterial injection of SIR-Spheres Y-90 resin microspheres (SIRT) followed 14-16 days later by systemic chemotherapy (ABC-02 CIS-GEM protocol) with an intention to treat with 8 cycles of cisplatin + gemcitabine, or until progression, toxicity or patient choice. Treatment may be continued beyond 8 cycles in the absence of significant disease progression, at the treating clinicians' discretion.
Drug: Cisplatin-gemcitabine
Systemic chemotherapy
Other Name: CIS-GEM
Device: Radiation: SIRT + chemotherapy (cisplatin-gemcitabine)
SIR-Spheres microspheres followed by systemic chemotherapy

Detailed Description:

This clinical study is a prospective, multicenter, randomized, controlled study evaluating SIR-Spheres Y-90 resin microspheres followed by cisplatin-gemcitabine (CIS-GEM) chemotherapy vs. CIS-GEM chemotherapy alone as first-line treatment of patients with unresectable intrahepatic cholangiocarcinoma.

Randomized patients will be followed until death, withdrawal of consent, or until end of study.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Willing, able and mentally competent to provide written informed consent.
  • Aged 18 years or older.
  • Histologically or cytologically confirmed unresectable and non-ablatable intrahepatic cholangiocarcinoma.
  • Liver-only or liver predominant intrahepatic cholangiocarcinoma. Patient are permitted to have loco-regional lymph node involvement defined as: portal LN </= to 2 cm and/or para aortic LN </= to 1.5 cm in longest diameter, and/or up to 2 indeterminate lung lesions < 1 cm if these lung lesions are positron emission tomography (PET) negative.
  • Chemotherapy naïve. Adjuvant chemotherapy is not permitted.
  • Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.
  • Adequate hematological function defined as:

Hemoglobin >/= 10g/dL White Blood Cell count (WBC) >/= 3.0 x 10^9/L Absolute neutrophil count (ANC) >/= 1.5 x 10^9/L Platelet count >/= 100,000/mm^3 - Adequate liver function defined as: Total bilirubin </= 30 umol/L (1.75 mg/dL) Albumin >/= 30 g/L

- Adequate renal function defined as: Serum urea and serum creatinine < 1.5 times upper limit of normal (ULN) Creatinine clearance >/= 45 ml/min (calculated with Cockcroft-Gault Equation)

  • Life expectancy of at least 3 months without any active treatment
  • Female patients must either be postmenopausal, sterile (surgically or radiation- or chemically-induced), or if sexually active use an acceptable method of contraception during the study.
  • Male patients must be surgically sterile or if sexually active must use an acceptable method of contraception during the study.
  • Considered suitable to receive either regimen in the clinical judgement of the treating investigator.

Exclusion Criteria:

  • Patients with only non-measurable lesions in the liver according to RECIST criteria
  • Incomplete recovery from previous liver surgery, e.g. unresolved biliary tree obstruction or biliary sepsis or inadequate liver function
  • Biliary stent in situ
  • Main trunk Portal Vein Thrombosis (PVT)
  • Ascites, even if controlled with diuretics. (A minor peri-hepatic rim of ascites detected at imaging is acceptable).
  • Mixed hepatocellular carcinoma - intrahepatic cholangiocarcinoma (HCC-ICC) disease
  • History of prior malignancy. Exceptions include in-situ carcinoma of the cervix treated by cone-biopsy/resection, non-metastatic basal and/or squamous cell carcinomas of the skin, recurrent intra-hepatic cholangiocarcinoma post local treatment or any early stage (stage 1) malignancy adequately resected with curative intent at least 5 years prior to study entry
  • Suspicion of any bone metastasis/metastases or central nervous system metastasis/metastases on clinical or imaging examination.
  • Prior internal or external radiation delivered to the liver.
  • Pregnancy; breast feeding.
  • Participation within 28 days prior to randomization, in an active part of another clinical study that would compromise any of the endpoints of the study.
  • Evidence of ongoing active infection that may affect treatment feasibility or outcome.
  • Prior Whipple's procedure.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT02807181

Contact: Florence Chow 49 228 1840 713

  Show 32 Study Locations
Sponsors and Collaborators
Sirtex Medical
Principal Investigator: Jordi Bruix, MD Head of the Hepatic Oncology Unit, Hospital Clinic
Principal Investigator: Harpreet Wasan, MD Imperial College Healthcare Hammersmith Hospital
  More Information

Responsible Party: Sirtex Medical Identifier: NCT02807181     History of Changes
Other Study ID Numbers: STX0115
Study First Received: May 13, 2016
Last Updated: April 4, 2017
Individual Participant Data  
Plan to Share IPD: No

Additional relevant MeSH terms:
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Antineoplastic Agents
Antimetabolites, Antineoplastic
Molecular Mechanisms of Pharmacological Action
Antiviral Agents
Anti-Infective Agents
Enzyme Inhibitors
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs processed this record on April 21, 2017